Last Posted: Jan 19, 2023
- Molecular profile of patients with myelofibrosis: a 10-year experience.
Dias Lara Faria Souza et al. Einstein (Sao Paulo, Brazil) 2023 21eAO0100
- The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance.
Rumi Elisa et al. International journal of molecular sciences 2020 Nov 21(23)
- Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A retrospective analysis from The Australasian Bone Marrow Transplant Recipient Registry.
Lwin Y et al. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2020 Aug
- [Analysis of gene mutations and clinic features in 108 patients with myeloproliferative neoplasm].
Tan Y X et al. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2020 Jul 41(7) 576-582
- Genomic characterization and prognostication applied to a Brazilian cohort of patients with myelofibrosis.
Nonino Alexandre et al. International journal of hematology 2020 Jun
- Mutational profiling in myelofibrosis: implications for management.
Bose Prithviraj et al. International journal of hematology 2019 Oct
- Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.
Barbui Tiziano et al. Leukemia 2018 32(5) 1057-1069
- Next-Generation Sequencing in Myeloproliferative Neoplasms: Is This Indicated in All Patients?
Mina Alain Antoine et al. Current hematologic malignancy reports 2019 Apr
- Next-generation sequencing with a 54-gene panel identified unique mutational profile and prognostic markers in Chinese patients with myelofibrosis.
Gill Harinder et al. Annals of hematology 2018 Dec
- Classification and Personalized Prognosis in Myeloproliferative Neoplasms.
Grinfeld Jacob et al. The New England journal of medicine 2018 379(15) 1416-1430
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Graves Disease
- Huntington Disease
- Myasthenia Gravis
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.